



This patient group direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

Patient Group Direction (PGD)

For the administration or supply of

Nystatin Oral Suspension

By registered health care professionals for

Management of Oral Candidiasis (Thrush) in Infants

Throughout the Manx Care and those contracted by the Manx Care where appropriate within practice

PGD NUMBER 132

1. Change history

Version number	Change details	Date
1	Original PGD ratified	June 2021

2. Medicines practice guideline 2: *Patient group directions*

Refer to the relevant sections of NICE medicines practice guideline 2: *Patient group directions* as stated in the blank template notes. For further information about PGD signatories, see the NHS and Manx Care [PGD website FAQs](#)

3. PGD development

Refer to the [NICE PGD competency framework for people developing PGDs](#)

Job Title & organisation	Name	Signature	Date
Author of the PGD			
Member of the PGD working group			

4. PGD authorisation

Refer to the [NICE PGD competency framework for people authorising PGDs](#)

Job Title	Name	Signature	Date
Medical Director			
Chief Pharmacist/ Pharmaceutical Adviser			
Senior Paramedic			
Director of Nursing			
GP Adviser			
Senior Microbiologist (if PGD contains antimicrobials)			

5. PGD adoption by the provider

Refer to the [NICE PGD competency framework for people authorising PGDs](#)

Job title and organisation	Signature	Date	Applicable or not applicable to area

6. Training and competency of registered healthcare professionals, employed or contracted by the Manx Care, GP practice or Hospice

Refer to the [NICE PGD competency framework for health professionals using PGDs](#)

	Requirements of registered Healthcare professionals working under the PGD
Qualifications and professional registration	<ul style="list-style-type: none"> Registered healthcare professionals, working within or contracted by the Manx Care, GP practice or Hospice who are permitted staff groups outlined within the current PGD policy Pharmacists must be practising in Manx Care authorised premises i.e. contracted pharmacy premises
Initial training	<ul style="list-style-type: none"> Knowledge of current guidelines and the administration of the drug specified in this PGD/BNF and of the inclusion and exclusion criteria Training which enables the practitioner to make a clinical assessment to establish the need for the medication covered by this PGD Local training in the use of PGD's
Competency assessment	Staff will be assessed on their knowledge of drugs and clinical assessment as part the competency framework for registered health professionals using PGD's
Ongoing training and competency	The registered health care professionals should make sure they are aware of any changes to the recommendations for this medication; it is the responsibility of the registered health care professionals to keep up to date with continuing professional development. PGD updates will be held every two years

7. Clinical Conditions

Clinical condition or situation to which this PGD applies	Oral Candidiasis (Thrush) in Infants
Inclusion criteria	Babies over 1 month and under 12 months of age with signs of oral thrush e.g. white plaques which do not move (not to be confused with milk curds in the mouth)
Exclusion criteria	<ul style="list-style-type: none"> • Infants with known hypersensitivity to any component • Infant is immunosuppressed • Patient / carer refuses treatment administered by a pharmacist under this Patient Group Direction
Cautions (including any relevant action to be taken)	<ul style="list-style-type: none"> • Contact with eyes and mucous membranes should be avoided • Registered healthcare professionals should check with the mothers of infants and if they are breastfeeding and also have sore nipples to refer both mother and baby to a prescriber (GP or HV) to obtain treatment for both • Where the baby is bottle fed, or where a breastfeeding mother is not experiencing any pain or other symptoms of thrush, the registered healthcare professional may supply Nystatin as per the Patient Group Direction
Arrangements for referral for medical advice	Patient should be referred to a more experienced clinical practitioner for further assessment
Action to be taken if patient excluded	Patient should be referred to a more experienced clinical practitioner for further assessment
Action to be taken if patient declines treatment	<ul style="list-style-type: none"> • A verbal explanation should be given to the patient on: the need for the medication and any possible effects or potential risks which may occur as a result of refusing treatment • This information must be documented in the patients' health records • Any patient who declines care must have demonstrated capacity to do so • Where appropriate care should be escalated

8. Details of the medicine

Name, form and strength of medicine	Nystatin Oral Suspension 100,000 units in 1ml
Legal category	Prescription Only Medicine (POM)
Indicate any <u>off-label use</u> (if relevant)	None
Route/method of administration	Oral – pipette provided
Dose and frequency	<ul style="list-style-type: none"> • Drop 1ml (100,000units) into the mouth four times daily after feeds • Continue treatment for 48 hours after condition has resolved

Quantity to be administered and/or supplied	Supply 1 x 30ml
Maximum or minimum treatment period	Maximum treatment period 7 days. If no improvement, or worsens, refer for further advice
Storage	Room temperature
Adverse effects	<ul style="list-style-type: none"> • abdominal distress • angioedema • diarrhoea • face oedema • nausea • sensitisation • skin reactions • Stevens-Johnson syndrome • vomiting
Records to be kept	The administration of any medication given under a PGD must be recorded within the patient's medical records

9. Patient information

Verbal/Written information to be given to patient or carer	<ul style="list-style-type: none"> • Verbal information must be given to patients and or carers for all medication being administered under a PGD • Where medication is being supplied under a PGD, written patient information leaflet must also be supplied • A patient information leaflet is available on request
Follow-up advice to be given to patient or carer	If symptoms do not improve or worsen or you become unwell, seek medical advice immediately

10. Appendix A

References
1. British National Formulary (BNF) available online: https://bnf.nice.org.uk
2. Nursing and Midwifery (2018) "The code" available online: https://www.nmc.org.uk
3. Current Health Care Professions Council standards of practice
4. General Pharmaceutical Council standards
5. The General Optical Council
6. Electronic medicines compendium available online: https://www.medicines.org.uk

11. Appendix B

Health professionals agreed to practice
<ul style="list-style-type: none"> • Each registered healthcare professional will hold their own Competency framework which will be signed and agreed by their mentor • A mentor is defined within the Manx Care policy as any ward/area managers, sisters, senior nurses, GPs, pharmacists or senior paramedics who has completed the PGD training themselves